High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer : an open-label, randomised, phase 2 trial
Background: Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer (SCLC). Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions is considered to be the most effective schedule. The aim of this study was to investigate whether high-dose, twice-daily thoracic radiotherapy of 60 Gy in 40 fractions improves survival. Methods: This open-label, randomised, phas
